Outcomes in 36 Patients with Stage IIIA-N2 Squamous Cell Carcinoma of the Lung Treated with Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy: A Prospective Study from a Single Center

Jianquan Zhu; Yu Zhang; Meng Wang; Zhenfa Zhang; Dongsheng Yue; Shichang Liu; Yi Pan; Changli Wang

doi:10.12659/MSM.930738

11 August 2021 : Clinical Research

Outcomes in 36 Patients with Stage IIIA-N2 Squamous Cell Carcinoma of the Lung Treated with Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy: A Prospective Study from a Single Center

Jianquan Zhu^1ABCDEF, Yu Zhang^1BC, Meng Wang^1BC, Zhenfa Zhang^1BC, Dongsheng Yue^1BC, Shichang Liu^2BC, Yi Pan^3BC, Changli Wang^1AE*

DOI: 10.12659/MSM.930738

Med Sci Monit 2021; 27:e930738

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 4 Adverse events of patients with squamous cell carcinoma of the lung treated with neoadjuvant nab-paclitaxel and carboplatin.

Event, n (%)	ITT (n=36)
Event, n (%)	Any grade	Grade 3 or 4
Neutropenia	17 (47.2)	6 (16.7)
Anemia	9 (25.0)	0
Leukopenia	9 (25.0)	0
Thrombocytopenia	3 (8.3)	0
Increased ALT	2 (5.6)	1 (2.8)
Increased bilirubin	1 (2.8)	1 (2.8)
ALT – alanine transaminase; ITT – intention-to-treat.

Back to the Article

Outcomes in 36 Patients with Stage IIIA-N2 Squamous Cell Carcinoma of the Lung Treated with Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy: A Prospective Study from a Single Center

Your Privacy